Fig. 2.
Fig. 2. Evolution of the BCR-ABL/ABL ratio in CML patients treated with IFN- (patients 1-10) or BMT (patient 16). / The BCR-ABL/ABL ratio kinetics for patient 16 is characteristic of a transient relapse. Other patients in CCR after BMT are not shown because they usually have BCR-ABL/ABL ratios close to 0.002%.

Evolution of the BCR-ABL/ABL ratio in CML patients treated with IFN- (patients 1-10) or BMT (patient 16).

The BCR-ABL/ABL ratio kinetics for patient 16 is characteristic of a transient relapse. Other patients in CCR after BMT are not shown because they usually have BCR-ABL/ABL ratios close to 0.002%.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal